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A B S T R A C T
Background
People with hemophilia A or B with inhibitors are at high risk of bleeding complications. Infusion of bypassing agents, such as
recombinant activated FVII (rFVIIa) and plasma-derived activated prothrombin complex concentrate, are suggested as alternative
therapies to factor VIII (haemophilia A) or IX (haemophilia B) for individuals who no longer respond to these treatments because they
develop inhibitory antibodies. The ultimate goal of treatment is to preserve the individual’s joints, otherwise destroyed by recurrent
bleeds.
Objectives
To assess the effects of bypassing agent prophylaxis to prevent bleeding in people with hemophilia A or B and inhibitors.
Search methods
We searched for relevant studies from the Cystic Fibrosis and Genetic Disorders Group’s Coagulopathies Trials Register, comprising
of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of
conference proceedings. We also searched trial registries (16 February 2017) and bibliographic references of retrieved studies were
reviewed for potential articles to be included in the review.
Date of the last search of the Cochrane Cystic Fibrosis and Genetic Disorders Coagulopathies Trials Register: 12 December 2016.
Selection criteria
We included randomized and quasi-randomized controlled studies (cross-over or parallel design) evaluating the effect of prophylaxis
treatment with bypassing agents compared with on-demand treatment, or studies evaluating the effects of high-dose compared with
low-dose prophylaxis in males of any age with hemophilia with inhibitors.
Data collection and analysis
Two authors independently selected studies and extracted data and assessed the risk of bias according to standard Cochrane criteria.
They assessed the quality of the evidence using the GRADE criteria.
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Main results
We included four randomized studies (duration 7 to 15 months) involving 116 males. Risk of bias was judged to be high in two studies
due to the open-label study design and in one study due to attrition bias.
Two studies compared on-demand treatment to prophylaxis with bypassing agents. In one study (34 males) prophylaxis significantly
reduced mean overall bleeding rates, MD - 7.27 (95% CI -9.92 to -4.62) (low quality evidence), mean number of overall bleeding
events per month, MD -1.10 (95% CI -1.54 to -0.66), mean number of hemarthrosis, MD -6.60 (95% CI -9.32 to -3.88) (low
quality evidence) and mean number of joints that had hemarthrosis, MD -0.90 (95% CI -1.36 to -0.44). The meta-analysis did not
conclusively demonstrate significant benefit of prophylaxis on health-related quality of life as measured by Haem-A-QoL score, EQ-
5D total score and utility score, EQ-5D VAS and SF-36 physical summary and mental summary score (low quality evidence for all
health-related quality of life analyses).
The remaining two studies compared dose regimens. The results from one study (22 males) did not conclusively demonstrate benefit
or harm of high-dose versus low-dose recombinant activated factor VIIa (rFVIIa) as a prophylaxis for overall bleeding rate, MD -0.82
(95% CI -2.27 to 0.63) (moderate quality evidence), target joint bleeding rate, MD -3.20 (95% CI -7.23 to 0.83) (moderate quality
evidence) and serious adverse events, RR 9.00 (95% CI, 0.54 to 149.50) (moderate quality evidence).
The overall quality of evidence was moderate to low due to imprecision from limited information provided by studies with small sample
sizes and incomplete outcome data in one study.
Authors’ conclusions
The evidence suggests that prophylaxis with bypassing agents may be effective in reducing bleeding in males with hemophilia with
inhibitors. However, there is a lack of evidence for the superiority of one agent over the other or for the optimum dosage regimen.
Further studies are needed to evaluate the benefits and harms of prophylaxis treatment on health-related quality of life, as well as the
effects of dose of bypassing agents on the outcomes.
P L A I N L A N G U A G E S U M M A R Y
The use of bypassing agents for preventing bleeding in people with hemophilia with inhibitors
Backgound
Infusion of bypassing agents, such as recombinant activated FVII (rFVIIa) and plasma-derived activated prothrombin complex concen-
trate (APCC), are suggested as alternative therapies to factor VIII (haemophilia A) or IX (haemophilia B) for individuals who no longer
respond to these treatments because they develop inhibitory antibodies. The ultimate goal of treatment is to preserve the individual’s
joints, otherwise destroyed by recurrent bleeds. We therefore evaluated the effectiveness and safety of bypassing agents when used to
prevent, as compared to treat, bleeds. We also compared different doses of bypassing agents in men with hemophilia A or B with
inhibitors as a preventative (prophylactic) therapy.
Search date
The evidence is current to 12 December 2016.
Study characteristics
We searched the scientific databases for clinical studies evaluating the effects of bypassing agents in men with hemophilia A or B with
inhibitors. We included four studies (duration 7 to 15 months), involving 116 individuals. Two studies compared the prophylactic
infusion with bypassing agent to on-demand treatment (treatment given only after the bleeding occurred) and two studies compared
high-dose to low-dose preventative therapies.
Key Results
Limited evidence showed that prophylactic use of bypassing agents reduced bleeding events, joint bleeding events and number of
affected joints. There was no evidence for improved quality of life amongst those who received prophylaxis as compared to those
who received on-demand therapy. There was no evidence for a difference in benefits or harms between high- and low-dose rFVIIa for
prophylaxis.
Quality of evidence
2Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The overall quality of evidence of these studies was moderate to low as the included studies were small and provided limited information.
Also, in one of the studies, up to 24% of the men recruited were not included in the analysis of the results, which further increases
imprecision of results.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Prophylaxis therapy compared with on-demand therapy with FEIBA for hemophilia A or B with inhibitors
Population: adults and children with hemophilia A or B with inhibitors
Settings: outpat ients
Intervention: prophylaxis therapy (FEIBA)
Comparison: on-demand therapy (FEIBA)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
On-demand Prophylaxis
Overall bleeding rates:
total number of bleed-
ing events
Follow-up: 6 months
Not est imable
(see comment)
The mean total num-
ber of bleeding events
in the prophylaxis group
was
7.27 lower than the
on-demand group (9.92
lower to 4.62 lower).
Not est imable
(see comment)
26
(1 study)1
⊕⊕©©
low2,3
Corresponding risk
(mean dif ference be-
tween groups) was es-
t imated taking account
of the cross-over de-
sign of the study. As-
sumed risk in the on-de-
mand group cannot be
direct ly calculated
Annualised bleeding
rate
Follow-up: 12 months
Median 28.7 (IQR, 32.3) The median annualised
bleeding rate was 7.9
(IQR8.1),which was 72.
5% lower than on-de-
mand group.
Not est imable
(see comment)
34
(1 study)
⊕⊕⊕©
moderate2
Data presented as me-
dian values and could
not be entered into anal-
ysis
Target joint bleed-
ing rate: number of
hemarthrosis
Follow-up: 6 months
Not est imable
(see comment)
The mean number of
hemarthrosis in the pro-
phylaxis group was
6.60 lower than the
on-demand group (9.32
lower to 3.88 lower).
Not est imable
(see comment)
26
(1 study)1
⊕⊕©©
low2,3
Corresponding risk
(mean dif ference be-
tween groups) was es-
t imated taking account
of the cross-over de-
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sign of the study. As-
sumed risk in the on-de-
mand group cannot be
direct ly calculated
AJBR
Follow-up: 12 months
Median 22.9 (IQR, 32.8) The median AJBR was
6.0 (IQR7.1),which was
73.8% lower than on-
demand group.
Not est imable
(see comment)
34
(1 study)
⊕⊕⊕©
moderate2
Data presented as me-
dian values and could
not be entered into anal-
ysis
Quality of life
Follow-up: 6 to 12
months
Not est imable
(see comment)
There were also no sig-
nif icant dif f erences be-
tween the prophylaxis
and on-demand treat-
ment for health-related
quality of lif e
Not est imable
(see comment)
up to 58
(2 studies)1
⊕⊕©©
low2,3
The health-related qual-
ity of lif e was mea-
sured using Haem-A-
QoL, Haemo-QoL, EQ-
5D, and general pain vi-
sual analog scale (VAS)
and the Short-Form (SF)
-36 Health survey
Safety of bypassing
agents
Follow-up: 6 to 12
months
Not est imable There were no throm-
boembolic event and
serious complicat ions
reported in part icipants
who received treatment
Not est imable
(see comment)
up to 67
(2 studies)1
⊕⊕©©
low2,3
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
AJBR: annualised joint bleeding rate; CI: conf idence interval; FEIBA: f actor eight inhibitor bypassing act ivity; IGR: interquart ile range
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. One study is of a cross-over design. 34 part icipants were randomized in the study but up to 24% of part icipants were
excluded f rom results.
2. Downgraded once due to imprecision; lim ited information available f rom one or two small studies.5
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3. Downgraded once due to risk of bias: incomplete outcome data, up to 24% of part icipants are excluded f rom analyses.
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B A C K G R O U N D
Description of the condition
Congenital deficiency of factor (F) VIII or FIX results in the for-
mation of alloantibodies which inhibit the activity of infused clot-
ting factor concentrates (CFCs) in approximately 30% of people
with severe (defined as less than 1 international unit (IU) dL ¹
baseline clotting factor activity) hemophilia A (FVIII deficiency)
and 2% to 5% of those with severe hemophilia B (FIX deficiency)
(Iorio 2010a).
In an analysis of the UK Haemophilia Centre Doctors’ Organ-
isation database, the cumulative risk of inhibitor formation was
16% and 36% at five years and 75 years of age (respectively) for
the 6078 males with hemophilia A and 6% and 8% (respectively)
for the 1172 males with hemophilia B (Darby 2004). The rate of
inhibitor formation is dependent on the residual or baseline circu-
lating FVIII or FIX level, being greatest in those people with severe
disease (Hay 1998). Among people with non-severe disease, those
with certain mutations, particularly in the A2 and C2 domains of
the F8 gene, are more likely to develop inhibitory antibodies.
Development of inhibitors is a complex process, but likely in-
cludes factors related to the individual being treated, the envi-
ronment and the treatment provided. Patient-related or geneti-
cally determined factors include ethnicity, race, the severity of the
hemophilia, hemophilia causing mutation, major histocompati-
bility class, and immunogenotype (Astermark 2010a). Environ-
mental or non-genetic factors are ones perceived by the immune
system as danger signals (Matzinger 1994; Matzinger 2012) and
may include the reason for the first infusion at a young age and
the intensity of treatment (Astermark 2010b).
Description of the intervention
Once the diagnosis of an inhibitor is made, treatment options in-
clude the management of acute bleeding, prevention of bleeding,
and immune tolerance induction (ITI), the latter being the pri-
mary treatment option (Collins 2013). One randomized prospec-
tive trial of ITI in children with favorable risk factors has been
completed (Hay 2012). Although 70% of participants had a com-
plete response to ITI, six of 37 participants relapsed after a median
of 9.5 months. Those in whom ITI failed or who relapsed after
successful ITI, along with those in whom ITI was not attempted
or those on ITI but still with bleeding, remain at risk for bleeding
and hence are candidates for prophylaxis with a bypassing agent.
Recombinant activated FVII (rFVIIa) and plasma-derived acti-
vated prothrombin complex concentrate (APCC) are currently
the only two bypassing agents available for use in people with
hemophilia with inhibitors. Two randomized trials of acute bleed-
ing management with bypassing agents have been completed, one
with rFVIIa (Young 2008) and one with APCC (Astermark 2007)
but neither involved a comparison of the prophylactic use of the
two drugs. These trials were reviewed in 2010 and superiority of
one treatment over the other in terms of hemostatic control or
thrombosis risk could not be demonstrated in participants with
acute bleeding (Iorio 2010b). Similarly, several non-randomized
studies failed to demonstrate superiority of one agent over the
other (Chuansumrit 2000; Kavakli 2006; Lusher 1998; Pruthi
2007; Santagostino 2006; Seremetis 1994; Shapiro 1998).
Frequent bleeding, especially joint bleeding, is a common disease
manifestation in people with hemophilia and inhibitors and im-
pacts overall health, joint health, and quality of life (Scalone2006).
Prophylaxis is the use of treatment on a regular basis to prevent
or reduce bleeding episodes. The choice of prophylactic infusion
requires the medication to be effective for bleeding management.
Therefore, prophylaxis in people with hemophilia with inhibitors
that do not respond to routine factor concentrates must rely on the
use of bypassing agents. In people without inhibitors, prophylaxis
is regarded as standard of care and is associated with a reduction
in musculoskeletal disease burden and with a good quality of life
(Iorio 2011). However, experience with prophylaxis is limited in
people with inhibitors.
In 2013, Collins recommended that prophylaxis with a bypassing
agent should be considered in childrenwith inhibitors after the first
hemarthrosis in an effort to prevent joint damage and in older peo-
ple with recurrent bleeding (Collins 2013). Regarding the choice
of bypassing agent, it was recommended that this decision be in-
dividualized based on prior response to treatment, logistics of ad-
ministration and cost. InOctober 2013, theMedical and Scientific
Advisory Council (MASAC) of theNational Hemophilia Founda-
tion recommended that prophylaxis with bypassing agents should
be considered in people with inhibitors (MASAC 2013). No spe-
cific guidelines were provided to guide clinicians who wished to
prescribe prophylaxis.
The optimal treatment for people with hemophilia without
inhibitors is the prophylactic administration of factor VIII
(hemophilia A) or factor IX (hemophilia B) concentrates (Iorio
2011). The development of neutralizing antibodies makes treat-
ment of bleeding with CFCs more difficult and when the concen-
tration of the antibody is above a certain level (≥ 5 Bethesda units
dL ¹ (BU)), replacement therapy is no longer effective (Berntorp
2006). In these cases with high titres of antibody, treatment with
bypassing agents, either rFVIIa or APCC, is necessary to control
acute bleeding (Shapiro 2003).
Prevention of bleeding or prophylaxis in cases with high titres of
antibody requires use of rFVIIa or APCC.
How the intervention might work
The development of anti-factor VIII or anti-factor IX antibodies
makes the administration of substitution therapy with factor VIII
or IX (respectively) ineffective. Bypassing agents are treatments
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that are able to activate the coagulation cascade independently of
factor VIII and IX; thus they are unaffected by the presence of
factor VIII or factor IX inhibitors. Bypassing agents, including
rFVIIa and APCC, have different mechanisms of action by which
they drive coagulation. It is known that rFVIIa activates factor Xa
on an activated platelet surface or when, it is bound to tissue factor,
it can directly activate thrombin. Alternatively, APCCmainly acts
by providing factors IX and X which are able to bypass the need
for FVIII to drive thrombin generation (Hedner 2000).
Prophylaxis with bypassing agents may prevent bleeding in people
with hemophilia with inhibitors and specifically reduce overall
bleeding rates and joint bleeding rates without excess thrombotic
and infectious risks. Ideally, prophylaxis with bypassing agents in
people with inhibitors will ensure long-term joint protection, in
the way that the prophylactic administration of factor VIII and
IX does in people without inhibitors.
Why it is important to do this review
The rationale for this review is that prophylaxis with bypassing
agentsmay improve the quality of life for peoplewith hemophiliaA
or Bwith inhibitors and reduce the economic burden of treatment.
This information may help to inform and guide clinicians in deci-
sion making when managing people with congenital hemophilia
and inhibitors.
O B J E C T I V E S
To assess the effects of bypassing agent prophylaxis to prevent
bleeding in people with hemophilia A or B and inhibitors.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled studies and quasi-randomized controlled
studies (cross-over or parallel design).
Types of participants
Males of any age with severe congenital hemophilia A or B compli-
cated by high-responding inhibitors to FVIII or FIX, respectively,
requiring a bypassing agent as prophylaxis to control or prevent
bleeding.
Types of interventions
Prophylaxis, at any dose, any dosing frequency, and any regimen,
of rFVIIa or APCC for preventing bleeding versus each other or
no prophylaxis.
Types of outcome measures
Primary outcomes
1. Overall bleeding events (per month), as defined by study
authors
Secondary outcomes
1. Annualised bleeding rate
2. Target joint bleeding rate
3. Annualised joint bleeding rate (AJBR)
4. Quality of life (QoL) (generic and specific validated scales
including EQ-5D, Haem-A-QoL, Haemo-QoL)
5. Safety of the bypassing agents including adverse events,
serious adverse events, or thromboembolic events
6. Cost and resource utilization when comparing prophylaxis
to on-demand treatment regimens, including overall drug
utilization
Search methods for identification of studies
There were no restrictions regarding language or publication sta-
tus.
Electronic searches
We identified relevant studies from theCystic Fibrosis andGenetic
Disorders Group’s Coagulopathies Trials Register using the terms:
(Factor VIII Inhibitors) OR (factor inhibitors).
The Coagulopathies Register was compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of The Cochrane Library),
weekly searches of MEDLINE and prospective hand-searching of
one specialized journal,Haemophilia. Unpublishedworkwas iden-
tified by searching the abstract books of five major conferences:
the EuropeanHaematology Association conference; the American
Society of Hematology conference; the British Society for Haema-
tology Annual Scientific Meeting; the International Society of
Haemostasis and Thrombosis Congresses; and the International
Congresses of World Federation of Haemophilia. For full details
of all searching activities for the register, please see the relevant
section of the Cochrane Cystic Fibrosis and Genetic Disorders
Group’s website.
Date of the last search of theCochrane Cystic Fibrosis andGenetic
Disorders Coagulopathies Trials Register: 12 December 2016.
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We also searched trial registries such as ClinicalTrials.gov (
www.clinicaltrials.gov) and the International Clinical Trials Reg-
istry Platform (www.who.int/ictrp/en/) in an attempt to identify
relevant studies for inclusion (Appendix 1). Date of most recent
search: 16 February 2017.
Searching other resources
The bibliographic references of retrieved studies were reviewed for
additional references to be included in this review.
Data collection and analysis
Selection of studies
Two review authors independently reviewed the abstracts from the
identified articles to select those that were potentially eligible to
be included in the review. The authors retrieved the full text re-
ports of studies that were deemed potentially relevant and linked
together multiple reports of the same study. The authors indepen-
dently examined the full text of the studies for compliance with
the eligibility criteria; and if necessary contacted the study inves-
tigators to determine study eligibility. The authors resolved any
disagreements on study inclusion by discussion in order to reach
a consensus.
Data extraction and management
A pair of authors (CC, SJN and MS) independently reviewed
the identified articles and extracted data on the following (a third
author arbitrated any differences).
1. Inclusion criteria for the study
2. Location and timeframe of the study
3. Participant number and demographics
4. Study methods
5. Study design
6. Type, characteristics and duration of the intervention and
control groups if applicable
7. Outcome measures and description
8. Information on limitations or bias (or both)
Assessment of risk of bias in included studies
A pair of authors (CC, SJN and MS) independently assessed the
risk of bias of the included studies. The risk of bias was assessed
using Cochrane’s tool for assessing the risk of bias according to the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011a). For each study, the risk of bias was noted as being either
’high risk’, ’low risk’, or ’unclear risk’ for the following criteria.
1. Sequence generation
2. Allocation concealment
3. Blinding of participant and personnel
4. Blinding of outcome assessment
5. Incomplete outcome data
6. Selected outcome reporting
7. Other issues
Measures of treatment effect
For the primary outcome, overall bleeding events were represented
as a mean number of bleeding events per month. Secondary out-
comes of target joint bleeding events and annualised joint bleeding
events were represented as a mean number of bleeding events per
month. We analyzed the data as continuous data, and reported
mean differences (MD) with the corresponding 95% confidence
intervals (CIs).
For safety outcomes, i.e. adverse events related to treatment, the
effect was presented as the proportion of males presenting the
event, and a risk ratio (RR). We calculated a pooled estimate of
the treatment effect for each outcome using the pooled RR and
95% CIs.
With respect to health-related quality of life (HRQoL), the mean
and standard deviation (SD) of scores from scales were presented.
We calculated the mean change from baseline for each group or
the mean post-intervention values and SD for each group. We
converted standard errors (SE) to SDs. We produced a pooled
estimate of treatment effect by calculating the MD and 95% CIs.
If economic data are reported in updates of this review, we will
analyse these data in the same way.
If for a future update, continuous scoresmeasure the same outcome
but in a variety of ways (e.g. different scales to measure knowledge
or quality of life), we plan to standardize the outcomes to a uniform
scale using the standardized MD (SMD).
Where studies reported multiple measures for the same outcome,
the review authors considered absolute changes in the measure in
the context of comparable data being available for each participant
before and after the intervention (i.e. change from baseline).The
authors recorded continuous data, such as joint score change, as
either mean change from baseline for each group or mean post-
treatment values (if change from baseline was not reported) and
SD for each group.
Unit of analysis issues
No cluster-randomized studies were identified. If cluster-random-
ized studies are identified for updates of the review, we will check
these studies for unit of analysis errors and perform analysis based
on the advice given in chapter 16 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011b).
When conducting a meta-analysis combining results from cross-
over studies, we used the methods recommended by Elbourne
(Elbourne 2002). We extracted (or calculated) MDs and SEs ad-
justed for the paired design of cross-over studies. If this had not
been possible, we would have considered whether data were pre-
sented by treatment period and include only first-period data in
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the analysis. If neither of these options were possible, we would
have included data from cross-over studies narratively in the re-
view.
We included one cross-over study in the review (Leissinger 2011).
For the outcome of overall bleeding events, we were able to extract
individual participant data from a graph and calculate a MD and
adjusted SE. We were also able to estimate that the correlation be-
tween treatment arms was around 0.4 from these data. Therefore,
we have used this correlation estimate to adjust estimates of SE for
other continuous outcomes measured in this study.
Dealing with missing data
If reports were incomplete, we attempted to contact the original
investigators in an effort to obtain the necessary data or infor-
mation. Where the original investigators could not provide addi-
tional information, we examined the proportion and distribution
of missing data (e.g. proportion of missing outcome data, demo-
graphic data, missing information regarding study designmethods
etc.). We also considered, where possible, whether data were likely
to be missing at random or not and whether the missing data were
likely to have had an impact on the results of the study.We judged
the risk of bias due to incomplete outcome data accordingly and
performed sensitivity analyses, excluding studies with large pro-
portions of missing data, if appropriate.
Assessment of heterogeneity
We assessed heterogeneity through visual examination of the com-
bined data presented in the forest plots, and by considering the
I² statistic together with Chi² values (significance level P < 0.1)
(Deeks 2011). The I² statistic reflects the likelihood that variation
of results across studies are due to heterogeneity rather than by
chance, and is interpreted as follows:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
We intended to assess publication bias by constructing, then visu-
ally inspecting, the funnel plot (where a minimum of 10 studies
could be included), and investigated outcome reporting bias by
comparing the methods and results sections of the published pa-
pers.
Data synthesis
Where meta-analysis could be conducted, we employed a fixed-ef-
fectmodel in the first instance. For future updates, whenmoderate
or higher heterogeneity is identified (I² of around 30% or higher),
a random-effects model will be employed. For dichotomous out-
comes (adverse events related to treatment), we employed theMan-
tel-Haenszel method of meta-analysis and present pooled RRs and
95%CIs. For continuous outcomes (overall bleeding events, annu-
alised bleeding rate, target joint bleeding events, annualised bleed-
ing events, HRQoL, economic data, joint score change), we em-
ployed the inverse variance method of meta-analysis and present
pooled MD or SMD (as appropriate, see Measures of treatment
effect) and 95% CIs.
Subgroup analysis and investigation of heterogeneity
If we had identifiedmoderate or higher heterogeneity (I² of around
30% or higher), we intended to investigate this by subgroup anal-
yses based on:
1. diagnosis (e.g. hemophilia A or B);
2. age of the participants (boys or adult males).
Sensitivity analysis
We intended to explore the impact of including studies with high
levels ofmissing data on the overall treatment effect, if appropriate.
Summary of findings and quality of the evidence
(GRADE)
In a post hoc change from protocol, we have presented a summary
of findings tables for each comparison in the review (Summary of
findings for the main comparison; Summary of findings 2).
The following outcomes were reported in the tables (chosen based
on relevance to clinicians and consumers): overall bleeding events;
annualised bleeding rate; target joint bleeding rate; AJBR; quality
of life; safety of the bypassing agents.
We determined the quality of the evidence using the GRADE
approach; and downgraded evidence in the presence of a high
risk of bias in at least one study, indirectness of the evidence,
unexplained heterogeneity or inconsistency, imprecision of results,
high probability of publication bias. We downgraded evidence by
one level if they considered the limitation to be serious and by two
levels if very serious (Balshem 2011; Guyatt 2008).
R E S U L T S
Description of studies
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
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We identified 96 citations from the database searches. We iden-
tified a further 89 references from searches of trial registries. Of
the total 185 references, we removed three duplicates. After we
reviewed the remaining titles and abstracts, 151 were discarded
as not being relevant and we retrieved the full-text references
(where possible) of nine studies (31 references). Of these, four
unique studies (reported in 26 references) were eligible random-
ized controlled studies and were included in the review (Antunes
2014; Konkle 2007; Leissinger 2011; Ljung 2013). We excluded
four studies (NCT02622321; NCT02795767; NCT02847637;
NCT03020160) and classified one study as awaiting further as-
sessment (NCT01105546).
Included studies
See Characteristics of included studies.
Four studies are included in the review (Antunes 2014; Konkle
2007; Leissinger 2011; Ljung 2013).
The Antunes study was a multicenter, parallel, randomized con-
trolled study conducted in 17 centers (Antunes 2014). Partici-
pants were enrolled if they were hemophilia A or B with a history
of high-titre inhibitor (> 5 BU/mL) or low-titre inhibitor (≤ 5
BU/mL) with refractory to increased dosing of factor replacement
therapy. A total of 17 participants were randomized to prophy-
laxis group and 19 were randomized to the on-demand therapy
group. Prophylaxis regimen was nanofiltered FVIII inhibitor by-
passing activity (FEIBA NF) 85 +/- 15 units/kg bolus infusion
every other day. Participants who were in the on-demand therapy
group received FEIBA NF administration when they experienced
a bleeding episode, dosing depended on type of bleeding. The
study lasted for 12 months. The primary outcome was annualised
bleeding rate. Secondary outcomes were AJBR, overall bleeding
events, target joint bleeding events, occurrence of new target joints,
hemostatic efficacy, total FEIBA NF utilization, safety and QoL.
The Konkle study was a multicenter, parallel, randomized con-
trolled study conducted in 20 centers (Konkle 2007). Participants
were enrolled if they had severe hemophilia A or B with a high
inhibitor titre (> 2 BU/mL), required treatment of bleeds with a
bypassing agent and had had at least four bleeds requiring hemo-
static drug treatmentwithin the previousmonth prior to enrolling.
There were three study periods (pre-prophylaxis, prophylaxis and
post-prophylaxis). Each period was for three consecutive months.
Eleven participants were randomized to rFVIIa 270 µg/kg once
daily and 11 were randomized to rVFIIa 90 µg/kg once daily. The
primary outcome was the number of bleeds per month. Secondary
outcomes were site-specific bleeding rates, safety, HRQoL and or-
thopedic joint scores.
The Leissinger studywas amulticenter, cross-over study conducted
in 16 centers (Leissinger 2011). Eligible participants were males
with severe hemophilia A and a history of high-titre inhibitor (> 5
BU/mL), who were older than two years of age, being treated with
bypassing agents and had six or more episodes of bleeding requir-
ing treatment in the six months prior to study enrollment. Pro-
phylaxis regimen was anti-inhibitor coagulant complex (AICC)-
FEIBA at a target dose of 85 (+/-15%) units/kg. During the on-
demand therapy period, participants received FEIBA at a dose
of 85 (+/-15%) units/kg if they experienced bleeding episodes. A
total of 17 participants were randomized to prophylaxis first (six
months of prophylaxis, followed by a three-month washout period
and six months of an on-demand period). A total of 17 partici-
pants were randomized to on-demand therapy first (six months of
on-demand therapy, followed by three months of washout period
and six months of prophylaxis). The primary outcome was to-
tal bleeding events (prophylaxis versus on-demand periods). Sec-
ondary outcomes were the number of joint bleeds, the number of
target joint bleeds, HRQoL and safety.
The Ljung study was a multicenter, parallel study conducted in
19 centers (Ljung 2013). Eligible participants had hemophilia A
or B with high titre inhibitor (≥ 5 BU/mL, frequent bleeds, age
12 to 65 years), had at least two bleeding episodes within the last
month or 12 bleeding episodes within the last six months prior to
enrolling. There were three study periods (three months of obser-
vation, followed by threemonths of prophylaxis and one month of
observation). The prophylaxis regimen was 40K glycoPEGylated
recombinant FVIIa bypassing agent (N7-GP) administered at tar-
get doses of 25 µg/kg, 100 µg/kg and 200 µg/kg intravenously
every second day. During the on-demand period, participants re-
ceived rFVIIa for the treatment of bleeding episodes. The primary
outcome was a reduction in the annualised bleeding rate (pro-
phylaxis versus on-demand therapy periods). Secondary outcomes
were the number of specific bleeds (stratified by sites) and causes
of bleeding.
Excluded studies
We identified four studies which were excluded from the
review (NCT02622321, NCT02795767, NCT02847637,
NCT03020160) as the study drug was neither rFVIIa or APCC.
Studies awaiting assessment
We identified one study which we are currently awaiting further
information on, once obtained, we will assess this for eligibility
(NCT01105546).
Risk of bias in included studies
See Figure 2 and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
13Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The Antunes study used centralised stratified, block randomiza-
tion (Antunes 2014), the Konkle study used centralised com-
puter-generated randomization (Konkle 2007) and the Leissinger
study conducted the randomization and treatment allocation by
using centralized call center (telephone randomization) (Leissinger
2011). Risk of selection bias was judged as ’low risk’ of bias for
these three studies. The Ljung study described that the partici-
pants were randomized and stratified by age (Ljung 2013). There
was no further information regarding random sequence genera-
tion and allocation concealment; the risk of bias for this study was
judged as ’unclear’.
Blinding
Two studies were open-label and there was no information regard-
ing the blinding of outcome assessors; therefore the risk of bias
was judged as ’high risk’ (Antunes 2014; Leissinger 2011). The
Konkle and Ljung studies described the blinding procedure as pro-
viding an equal volume of trial drug to be injected in both groups
(Konkle 2007; Ljung 2013). There was no information regarding
blinding of the outcome assessors; the risk of bias was judged as
’low risk’ for the latter studies.
Incomplete outcome data
The Antunes study reported that two participants withdrew
from the on-demand group and one from the prophylaxis group
(Antunes 2014). The Ljung study reported that three participants
withdrew during the study period (one from the 100 µg/kg group
and one from the 200 µg/kg group) (Ljung 2013). There were no
withdrawals during the study period in the Konkle study (Konkle
2007). All participants were included in an intention-to-treat anal-
ysis. The participants were well balanced across groups. The risk
of bias was judged to be ’low risk’ for these three studies. The
Leissinger study reported that one participant withdrew consent
before receiving the study medication and a further seven did not
complete the study; the risk of bias was judged as ’high risk’ for
this study (Leissinger 2011).
Selective reporting
All of the studies clearly specified primary and secondary out-
comes. The data on all outcomes were reported. There was no ev-
idence of selective reporting, therefore, the risk of bias was judged
to be ’low risk’ for all four studies.
Other potential sources of bias
All four studies were deemed to be at ’low risk’ of bias from other
source of bias.
Effects of interventions
See: Summary of findings for the main comparison Prophylaxis
therapy compared with on-demand therapy with FEIBA for
hemophilia A or B with inhibitors; Summary of findings 2
High-dose compared with low-dose rFVIIa for hemophilia A or
B with inhibitors
Two comparisons were made in this review, prophylaxis compared
to on-demand therapy and low-dose compared to high-dose ther-
apy.
Prophylaxis compared to on-demand therapy
Two studies recruiting 70 participants contributed to this com-
parison (Antunes 2014; Leissinger 2011). Both studies compared
prophylaxis to on-demand therapy with FEIBA (AICC or NF).
Primary outcome
1. Overall bleeding rates (per month)
One study reported on the bleeding rate per month (over a six-
month period) on prophylaxis and on-demand therapy (Leissinger
2011). At six months, prophylaxis with bypassing agent (FEIBA)
significantly reducedmean overall bleeding rates,MD -7.27 (95%
CI -9.92 to -4.62) (low quality evidence) (Analysis 1.1) and the
mean number of overall bleeding per month, MD -1.10 (95% CI
-1.54 to -0.66) compared with those who are on-demand group
(Analysis 1.2).
Secondary outcomes
1. Annualised bleeding rates
One study reported on annualised bleeding rates; however, data
were presented as median values and cannot be entered into anal-
ysis (Antunes 2014). The median annualised bleeding rate was
significantly lower among those who were allocated to prophylaxis
as compared to on-demand treatment (7.9 versus 28.7) (moderate
quality evidence).
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2. Joint bleeding rates
One study reported mean number of hemarthrosis (Leissinger
2011). At six months, prophylaxis with bypassing agent (FEIBA)
significantly reduced mean number of hemarthrosis, MD -6.60
(95% CI -9.32 to -3.88) when compared to on-demand treat-
ment (low quality evidence) (Analysis 1.3). Mean number of joint
hemorrhages was significantly lower among those who were on
prophylaxis, MD -0.90 (95% CI -1.36 to -0.44) when compared
to those with on-demand therapy (Analysis 1.4).
3. AJBR
One study reported on annualised bleeding rates; however, data
were presented as median values and cannot be entered into anal-
ysis (Antunes 2014). The median AJBR was significantly lower
among those whowere allocated to prophylaxis as compared to on-
demand treatment (6.0 versus 22.9) (moderate-quality evidence).
4. Quality of life
Two studies reported outcome regarding to HRQoL (low-quality
evidence) (Antunes 2014; Leissinger 2011). The Antunes study
evaluated HRQoL using the Haem-A-QoL, Haemo-QoL, EQ-
5D, and general pain visual analog scale (VAS) at six and 12
months (Antunes 2014). Leissinger assessed HRQoL using the
EQ-5D questionnaire and the Short-Form (SF)-36 Health survey
(Leissinger 2011).
After 12 months of study, mean change from baseline of Haem-A-
QoL score was not significantly different but in favour of prophy-
laxis as compared with on-demand treatment, MD 3.40 (95% CI,
-5.53 to 12.33) (Analysis 1.5). Mean change from baseline of EQ-
5D scores were not significantly different but in favour prophy-
laxis, measuring at six months, MD 0.09 (95% CI -0.09 to 0.27)
and 12 months, MD 0.07 (95% CI -0.13 to 0.27) (Analysis 1.6).
Mean change from baseline of EQ-5D VAS was not significantly
different but in favour prophylaxis, measuring at six months, MD
4.11 (95% CI, -3.66 to 11.88) and 12 months, MD 9.90 (95%
CI, -5.93 to 25.73) (Analysis 1.7). Mean change from baseline of
EQ-5D utility score were not statistically different between pro-
phylaxis and on-demand group, MD 0.00 (95% CI -0.12 to 0.12)
(Analysis 1.8). The mean change from baseline of SF36-physical
summary score was not significantly different comparing between
prophylaxis and on-demand treatment at six months, MD 2.90
(95%CI -1.53 to 7.33) (Analysis 1.17). Likewise, themean change
from baseline of SF36-mental summary score was not significantly
different comparing between prophylaxis and on-demand treat-
ment at six months, MD 1.20 (95% CI -2.75 to 5.15) (Analysis
1.18). There were also no significant differences between the treat-
ments for any of the individual SF-36 physical or mental domains
(Analysis 1.9; Analysis 1.10; Analysis 1.11; Analysis 1.12; Analysis
1.13; Analysis 1.14; Analysis 1.15; Analysis 1.16).
5. Safety of the bypassing agents
Two studies reported on the safety of the bypassing agents (low
quality evidence) (Antunes 2014; Leissinger 2011). Antunes re-
ported 36 (28.8%) of treated participants in two groups experi-
enced serious adverse effects (Antunes 2014). No study reported
thromboembolic events or major safety issues. Leissinger reported
that one participant had an allergic reaction to the study drug
during prophylaxis and three participants had events related to
central venous access during prophylaxis and on-demand therapy
(Leissinger 2011).
6. Cost and resource utilization
Neither study reported this outcome (Antunes 2014; Leissinger
2011)
High-dose compared to low-dose prophylaxis therapy
Two studies recruiting 46 participants contributed to this compar-
ison (Konkle 2007; Ljung 2013). Both compared doses of rFVIIa;
Konkle compared 270 µg/kg to 90 µg/kg and Ljung compared
three doses of 200µg/kg, 100µg/kg and 25µg/kg (Konkle 2007;
Ljung 2013).
Primary outcome
1. Overall bleeding rate (per month)
One study reported the overall bleeding rates comparing high-dose
(270 µg/kg) versus low-dose (90 µg/kg) rFVIIa (Konkle 2007).
High-dose rFVIIa reduced the mean number of bleeds per month
when compared to low-dose rFVIIa, but the difference between
the groups was not statistically significant, MD -0.82 (95% CI -
2.27 to 0.63) (moderate quality evidence) (Analysis 2.1).
Ljung reported the mean annualised bleeding rate per month,
comparing three doses of rFVIIa (200 µg/kg, 100 µg/kg and 25
µg/kg) (Ljung 2013). The mean annualised bleeding rates per
month were reduced during prophylaxis as compared to the on-
demand treatment period for all three doses of rFVIIa. The bleed-
ing rate could not be analysed between the groups due to the in-
adequate outcome reports.
Secondary outcomes
1. Annualised bleeding rates
Ljung reported annualised bleeding among those who received
three different doses of rFVIIa (Ljung 2013). As compared to on-
demand treatment period, the annualised bleeding rate during
prophylaxis were reduced by 36%, 45% and 52% in participants
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who received rFVIIa 200 µg/kg, 100 µg/kg and 25 µg/kg, re-
spectively. The bleeding rate could not be analysed between the
groups due to the inadequate outcome reports.
2. Joint bleeding rate
One study reported target joint bleeding rates comparing high-
dose (270 µg/kg) versus low-dose (90 µg/kg) rFVIIa (Konkle
2007). At three months, high-dose rFVIIa reduced mean joint
bleeding rates when compared to low-dose rFVIIa but the differ-
ence between the groups was not statistically significant, MD -
3.20 (95%CI -7.23 to 0.83) (moderate quality evidence) (Analysis
2.2).
3. AJBR
Neither study reported this outcome (Konkle 2007; Ljung 2013).
4. Quality of life
Neither study reported this outcome (Konkle 2007; Ljung 2013).
5. Safety of the bypassing agents
Two studies reported adverse events comparing high-dose versus
low-dose rFVIIa (Ljung 2013; Konkle 2007). There was no sta-
tistical difference of the risk of adverse events between doses, RR
1.00 (95% CI 0.57 to 1.76) for 200 µg/kg compared to 100 µg/
kg, RR 1.50 (95%CI 0.67 to 3.34) for 200 µg/kg compared to 25
µg/kg, RR 1.50 (95% CI 0.67 to 3.34) for 100 µg/kg compared
to 25 µg/kg and RR 0.89 (95% CI 0.56 to 1.40) for 270 µg/
kg compared to 90 µg/kg (moderate-quality evidence) (Analysis
2.3).
One study reported serious adverse events comparing high-dose
versus low-dose rFVIIa (Konkle 2007). Four participants who
received high-dose rFVIIa (270 µg/kg) reported serious adverse
events compared to no participants who received low-dose (90µg/
kg). However, this difference between groups was not statistically
significant, RR 9.00 (95% CI 0.54 to 149.50) (Analysis 2.4).
6. Cost and resource utilization
Neither study reported this outcome (Konkle 2007; Ljung 2013)
17Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
High-dose compared with low-dose rFVIIa for hemophilia A or B with inhibitors
Population: adults and children with hemophilia A or B with inhibitors
Settings: outpat ients
Intervention: high-dose therapy (rFVIIa)
Comparison: low-dose therapy (rFVIIa)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Low dose High dose
Overall bleeding rates:
number of bleeds per
month
Follow-up: 3 months
The mean number of
bleeds per month in the
low-dose group was 2.
18
The mean number of
bleeds per month in the
high-dose group was 0.
82 lower than the low-
dose group (2.27 lower
to 0.63 higher).
Not est imable 22
(1 study)
⊕⊕⊕©
moderate1
An addit ional study re-
cruited part icipants to
200 µg/ kg, 100 µg/ kg
and 25 µg/ kg. Results
showed reduct ion of
overall bleeding rates
for all 3 groups dur-
ing prophylaxis as com-
pared to on-demand pe-
riod. (Data could not be
entered into analysis as
SDs not presented.)
Annualised bleeding
rate
Follow-up: 3 months
Not est imable
(see comment)
Not est imable
(see comment).
Not est imable
(see comment)
24
(1 study)
NA Results showed reduc-
t ion of overall bleed-
ing rates for all 3
groups during prophy-
laxis as compared to
on-demand period
(Data could not be en-
tered into analysis as
SDs not presented.)18
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Target joint bleeding
rate
Follow-up: 3 months
The mean number of
joint bleeds per month
in the low-dose group
was 4.7
The mean number of
bleeds per month in the
high-dose group was 3.
20 lower than the low-
dose group (7.23 lower
to 0.83 higher).
Not est imable 22
(1 study)
⊕⊕⊕©
moderate1
AJBR
Follow-up: 3 months
Outcome not reported. NA
Quality of life
Follow-up: NA
Outcome not reported. NA
Safety of bypassing
agents
There were no signif icant dif f erences between
doses in terms of adverse events or serious
adverse events (see comment)
Not est imable 46
(2 studies)
⊕⊕⊕©
moderate1
Doses compared were:
270 µg/ kg and 90 µg/
kg
200 µg/ kg and 100 µg/
kg
200 µg/ kg and 25 µg/
kg
100 µg/ kg and 25 µg/
kg.
* The basis for the assumed risk is the event rate in the control group. The corresponding risk (and its 95%conf idence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervent ion (and its 95%CI).
AJBR: annualised joint bleeding rate; CI: conf idence interval; NA: not applicable; rFVIIa: recombinant factor VIIa; SD: standard deviat ion
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Downgraded once due to imprecision; lim ited information available f rom one or two small studies.
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D I S C U S S I O N
Summary of main results
Four studies were found to be eligible for the review (Antunes
2014; Konkle 2007; Leissinger 2011; Ljung 2013). Two stud-
ies compared prophylaxis versus on-demand treatment (Antunes
2014; Leissinger 2011) and two studies compared high to low
doses of bypassing agents for prophylaxis (Konkle 2007; Ljung
2013). The main findings of this Cochrane Review and meta-
analysis in people with hemophilia with inhibitors suggested that
prophylaxis with bypassing agents reduces overall bleeding rates
and joint bleeding rates as compared to on-demand treatment.
No statistically significant differences in change from baseline for
HRQoL were found and this review did not conclusively rule out
benefit or harm of high-dose compared with low-dose rFVIIa.
Overall completeness and applicability of
evidence
All of the included studies enrolled people with hemophilia A
or hemophilia B with inhibitors. Two studies compared pro-
phylaxis with on-demand treatment (Antunes 2014; Leissinger
2011). However, the remaining two studies did not include partic-
ipants who were given on-demand treatment as a control (Konkle
2007; Ljung 2013). The prophylactic durations ranged from three
months to 12 months. The data were presented differently (e.g.
crude bleeding rate, annualised bleeding rate or bleeding per
month) and reported in mean or median. Consequently, meta-
analyses were prevented in some cases. Two studies evaluated
HRQoL; however, the tools used in these studies varied (Antunes
2014; Leissinger 2011). Consequently, a pooled analysis could
not be performed for the majority of HRQoL domains. Although
we observed statistically significant differences of the clinical out-
comes regarding to the reduction of overall bleeding rates and
joint bleeding rates in those who were allocated to prophylaxis as
compared to on-demand treatment, the clinical relevance of this
finding warrant further prospective studies with a greater number
of participants and a longer duration of follow-up.
Although the studies included in this review were conducted as
multicenter, multinational studies; bypassing agents as a prophy-
laxis in people with hemophilia with inhibitors are not widely used
in countries where the resources are limited. Hence, the applica-
bility of this evidence to certain groups of people with hemophilia
A or B is limited.
Quality of the evidence
When comparing between prophylaxis versus on-demand treat-
ment, the quality of the evidence was moderate for outcomes re-
lating to annualised bleeding rates; we downgraded the evidence
due to the imprecision of limited data from one or two small stud-
ies. Other outcomes (bleeding rates, HRQoL and safety) provided
low quality evidence for this comparison; in addition to impreci-
sion, evidence was also downgraded due to incomplete outcome
data with up to 24% of participants excluded from one cross-over
study.
When comparing high-dose to low-dose rFVIIa, the quality of ev-
idence was moderate for overall bleeding rates, target joint bleed-
ing rate and safety of bypassing agents; we downgraded evidence
due to imprecision of limited data from one or two small studies.
Other outcomes were not reported for this comparison.
Potential biases in the review process
We performed extensive searches for this Cochrane Review. The
methodology regarding study selection, data extraction, risk of bias
assessment and analyses were rigorously conducted. We contacted
the corresponding authors for clarification on data; however, there
were some missing reported outcomes regarding overall bleeding
rate, joint bleeding rate and health-related outcomes. In addition,
the small number of included studies in this review precluded us
from conducting subgroup analyses.
Agreements and disagreements with other
studies or reviews
Valentino conducted a systematic review of six observational stud-
ies, involving 34 hemophilia people with inhibitors who were
treated with FEIBA for prophylaxis (Valentino 2010). The me-
dian prophylactic dose was 78.5 unit per kg. There was 63.9%
reduction in overall bleeding events and 73% reduction in annual
joint bleeding.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence suggests that prophylaxis with bypassing agent may
be effective in people with hemophilia A or B with inhibitors for
the reduction of overall bleeding rates and joint bleeding rates
(low to moderate quality evidence). There is insufficient evidence
to show that prophylaxis does affect health-related quality of life
(HRQoL) as compared to on-demand treatment (low quality ev-
idence). There is lack of evidence of superiority of one agent over
the other as well as the dosage regimen.
Implications for research
The small sample sizes and substantial attrition rates of the in-
cluded studies limited the precision of the effect estimates. Larger
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prospective studies are warranted in order to evaluate the efficacy
of prophylaxis compared to on-demand treatment and high-dose
versus low-dose regimen of bypassing agents. In addition, out-
come measures (such as bleeding event and HRQoL) were non-
uniformly reported. Consequently, it is difficult to compare the re-
sults across the studies and to performmeta-analyses.Hemophilia-
specific tools for assessing HRQoL may be more informative and
uniform. The hemophilia research community needs to develop a
consensus on measuring and reporting outcomes in hemophilia-
related literature.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Antunes 2014
Methods Multicenter parallel randomized study conducted in 17 centres in Bulgaria, Russia,
Croatia, Poland, Romania, USA, Japan and Brazil
Participants 36 males (prophylaxis (n = 17) or on-demand therapy (n = 19))
Inclusion criteria: hemophilia A or B with documented history of high-titre inhibitor (>
5 BU/mL) or low-titre inhibitor (≤ 5 BU/mL) refractory to increased dosing of either
FVIII or FIX for at least 12 months; were≥ 4 and≤ 65 years of age; were currently being
treated on demand with bypassing agents; had ≥ 12 bleeding episodes in the previous
12 months; and a negative HIV status, or if positive, with a stable CD4 count
Exclusion criteria: symptomatic liver disease; had platelet count < 100,000 per µL; were
currently receiving ITI or prophylaxis; needed elective surgery; needed alpha-interferon
or protease inhibitor use; or had previous thromboembolic events
Interventions Prophylaxis: FEIBA NF 85 +/- 15 units/kg intravenously bolus infusion every other day
On demand: FEIBA NF, dosing depended on type of bleeding and was at discretion of
the investigator
Duration of treatment: 12 months (+/- 14 days)
Outcomes Primary outcome: annualised bleeding rate
Secondary outcomes: AJBR, overall bleeding events, target joint bleeding events, occur-
rence of new target joints, hemostatic efficacy, total FEIBA NF utilization, safety and
quality of life
Notes Study sponsored by Baxter Healthcare Corporation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomization in a 1:1 ratio with
stratification by geography (block size not
stated)
Allocation concealment (selection bias) Low risk The randomization scheme was centralized
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label study
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Antunes 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 participants withdrew from on-demand
group (1 serious adverse event and 1
surgery) and 1 from the prophylaxis group
(adverse event). Withdrawal rate similar
across groups and all participants included
in an ITT analysis
Selective reporting (reporting bias) Low risk No protocol available. All outcomes de-
fined in themethods reported in the results,
no evidence of selective reporting
Other bias Low risk None identified
Konkle 2007
Methods Multicenter randomized parallel study conducted across 20 sites in Argentina, Brazil,
Bulgaria, the Philippines, Poland, Romania, Russia, South Africa, Spain, Turkey and
USA
Participants 22 participants (rFVIIa 270 µg/kg (n = 11) and rFVIIa 90 µg/kg (n = 11))
Inclusion criteria: males with severe congenital hemophilia A or B with a high docu-
mented history of inhibitor titre (with an inhibitor titre > 2 BU/mL in the preceding
12 months), a requirement for current treatment of bleeds with bypassing agents, and at
least four bleeds requiring hemostatic drug treatment (except dental bleeds and bruises)
within the previous month
Exclusion criteria: prophylaxis with any hemostatic drug within the last 3 months, ITI
within the last month, known pseudotumours, platelet count < 50,000 per µL, ad-
vanced atherosclerotic disease, and congenital or acquired coagulation disorders other
than hemophilia A or B
Interventions There were 3 phases of 3-month study period (pre-prophylaxis, prophylaxis and post-
prophylaxis periods)
Prophylaxis with high dose: activated rFVIIa 270 µg/kg once daily, slow bolus intra-
venously over a period of 2 minutes
Prophylaxis with low dose: rFVIIa 90 µg/kg once daily
Outcomes Primary outcome: number of bleeds per month comparing between during the prophy-
laxis period and pre-prophylaxis period
Secondary outcomes: number of bleeds per month comparing between post-prophylaxis
period and prophylaxis period, site specific bleeding rates, safety, HRQoL, orthopedic
joint scores
Notes On-demand treatments of acute/breakthrough bleeds were continued as normal practice
throughout the study. 38 participants were originally recruited for the study, 37 entered
the pre-treatment observation period but 15 were withdrawn
Study sponsored by Novo Nordisk
Risk of bias
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Konkle 2007 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralized computer-generated random-
ization list was used to randomly allocate
participants
Allocation concealment (selection bias) Low risk Centralized computer-generated random-
ization list was used to randomly allocate
participants
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was maintained by providing an
equal volume of study drug to be injected
in both groups
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals during the study period.
All randomized participants analysed, ITT
approach used
Selective reporting (reporting bias) Low risk No protocol available. All outcome defined
in the methods mentioned in the results,
some outcomes reported in more detail
than others (e.g. no numerical results re-
ported for orthopedic status)
Other bias Low risk None identified
Leissinger 2011
Methods Multicenter randomized cross-over study conducted at 16 centres in Europe and USA
Participants 34 participants
Inclusion criteria: severe hemophilia A and a history of a factor VIII inhibitor titre
exceeding 5 BU, older than 2 years old, being treated with bypassing agents and had 6
or more episodes of bleeding requiring treatment in the 6 months before the study
Exclusion criteria: receiving immune tolerance therapy, regular prophylaxis with any
hemostatic agent, symptomatic liver disease, platelet count of less than 100,000 per
µL, planned elective surgery within 12 months, used an investigational product within
1 month of study enrolment, planned to begin treatment with interferon or protease
inhibitor
Interventions Prophylaxis: AICC (FEIBA) administration at a target dose of 85 units/kg (+/- 15%) on
3 non-consecutive days weekly
On demand: AICC at a target dose of 85 units/kg (+/- 15%) for bleeding episode
Duration of treatment: 6 months of prophylaxis, 3 months of washout period and 6
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Leissinger 2011 (Continued)
months of on-demand therapy (prophylaxis first), 6 months of on-demand therapy, 3
months of washout period and 6 months of prophylaxis (on-demand therapy first)
Outcomes Primary outcome: reduction of bleeding events during prophylaxis period compared
with the on-demand period
Secondary outcomes: number of joint bleeding, number of target joint bleeding,HRQoL
and safety
Notes Study funded by Baxter Bioscience who provided AICC. Study investigators and a med-
ical writer paid by Baxter Bioscience prepared the manuscript
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization conducted from a central-
ized call center (telephone randomization)
- information from the online protocol
Allocation concealment (selection bias) Low risk Randomization conducted from a central-
ized call center (telephone randomization)
- information from the online protocol
Blinding of participants and personnel
(performance bias)
All outcomes
High risk For ethical and practical reasons, partici-
pants were aware of study assignments
Blinding of outcome assessment (detection
bias)
All outcomes
High risk For ethical and practical reasons, partici-
pants were aware of study assignments
Incomplete outcome data (attrition bias)
All outcomes
High risk Per protocol results reported for efficacy
outcomes (reduction in bleeding rates /
joint bleeding rates), ITT approach for sa-
fety outcomes (monthly hemorrhage rates,
adverse effects)
Up to 24% of participants excluded from
results: 1 patient withdrew consent be-
fore receiving study medication. The ITT
group comprised 33 participants, of whom
7 did not complete the study: 1 withdrew
because of an allergic reaction, 2 died, 1was
lost to follow-up after Hurricane Katrina,
and 3 withdrew consent (2 during the on-
demand period and 1 during the prophy-
laxis period)
28Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Leissinger 2011 (Continued)
Selective reporting (reporting bias) Low risk Online protocol available. All outcomes re-
ported in protocol fully reported in the
study, no evidence of selective reporting
Other bias Low risk None identified
Ljung 2013
Methods Multicenter randomizedparallel study conducted over 19 sites inFrance, Japan,Malaysia,
Serbia, Sweden, Turkey, UK, USA, South Africa
Participants 24 participants (8 to each group but 1 not dosed)
Inclusion criteria: people with hemophilia A or B with high-responding inhibitors (≥ 5
BU/mL) and frequent bleeds, age 12 - 65 years, at least 2 bleeding episodes within the
last month or 12 bleeding episodes within the last 6 months
Exclusion criteria: lowplatelet count (< 50,000 perµL), active pseudotumours, advanced
atherosclerotic disease, severe liver disease, renal dysfunction, coagulation disorders other
than congenital hemophilia or a history of thromboembolic events
Interventions On-demand period: activated rFVIIa for the treatment of bleeding episodes
Prophylaxis period: 40K glycoPEGylated rFVIIa bypassing agent (N7-GP) administra-
tion at a target doses of 25, 100 and 200 µg/kg intravenously over 2 - 5 minutes every
second day
Duration of the study: 3 months of observation period (on-demand therapy), 3 months
of prophylaxis period and 1 month of observation period
Outcomes Primary outcome: reduction in annualised bleeding rate
Secondary outcome: number of specific bleeds stratified by sites and causes
Notes Study sponsored by Novo Nordisk
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomized and stratified by
age, no further information given regarding
generation of random sequence
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study: placebo solution was
used to provide equal injection volume ir-
respective of dose
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Ljung 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 participants were withdrawn during the
treatment period (1 from100µg group and
2 from200µg group) but all were included
in analyses up to the point of withdrawal
in an ITT analysis
Selective reporting (reporting bias) Low risk No protocol available. Most outcomes de-
fined in the methods reported in the results
(target joint rate bleeds mentioned in the
methods but not in the results). The study
is a Phase 2 dose ranging study so the main
objective of the study is safety and pharma-
cokinetic measures, efficacy is a secondary
measure so risk of bias is judged to be low
Other bias Low risk None identified
AICC: anti-inhibitor coagulant complex
AJBR: annualised joint bleeding rate
BU: Bethesda unit
FEIBA NF: nanofiltered factor eight inhibitor bypassing activity
HRQoL: health-related quality of life
ITI: immune tolerance induction
ITT: intention-to-treat
rFVIIa: recombinant factor VII
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
NCT02622321 The study drug was not rFVIIa or APCC
NCT02795767 The study drug was not rFVIIa or APCC
NCT02847637 The study drug was not rFVIIa or APCC
NCT03020160 The study drug was not rFVIIa or APCC
APCC: activated prothrombin complex concentrate
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rFVIIa: recombinant factor VIIa
Characteristics of studies awaiting assessment [ordered by study ID]
NCT01105546
Methods Multicenter parallel study in the USA, France, Germany, Italy, Romania and Spain
Participants Inclusion criteria: boys with hemophilia A who developed FVIII inhibitors, up to 8 years, ≤ 2 years from the time
of inhibitor detection, high-responding inhibitor (≥ 5 BU/mL) and known anamnestic response in case of negative
inhibitor titre, candidate to start ITI with FVIII concentrates (doses ranging from 50 IU/kg/day to 200 IU/kg/day),
≤ 2 bleedings in the same joint within the last 6 months before entering the study, maximum 6 joint bleeds in the
same joint within 2 years and adequate venous access
Exclusion criteria: ITI already started, sensitivity to study drug, administration of study drug within 30 days prior
randomization, family history of thrombosis at early age (< 40 years), known thrombophilia, any previous thrombosis,
known pseudotumors, severe liver disease, platelet count < 50,000 platelet/µL and surgery within 1month or planned
for major surgery
Interventions On demand: on-demand treatment, treatment of bleeding episodes with rFVIIa 270 µg/kg (first/single dose) or 90
µg/kg IV every 2-3 hours until bleeding resolution
Prophylaxis: prophylaxis with rFVIIa 90 µg/kg/day
Outcomes No information provided
Notes Study sponsored by Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico
ITI: immune tolerance induction
IU: international units
IV: intravenous
rFVIIa: recombinant factor VIIa
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D A T A A N D A N A L Y S E S
Comparison 1. Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight
inhibitor bypassing activity (FEIBA NF)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall bleeding rates: total
number of bleeding events
1 Mean Difference (Fixed, 95% CI) Totals not selected
1.1 at 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Overall bleeding rates: number
of monthly bleeding events
1 Mean Difference (Fixed, 95% CI) Totals not selected
2.1 up to 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Target joint bleeding rate:
number of hemarthroses
1 Mean Difference (Fixed, 95% CI) Totals not selected
3.1 at 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Target joint bleeding rate:
number of joint hemorrhages
1 Mean Difference (Fixed, 95% CI) Totals not selected
4.1 at 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Health-related QoL: change
from baseline in total
Haem-A-QoL score
1 Mean Difference (Fixed, 95% CI) Totals not selected
5.1 at 12 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Health-related QoL: change
from baseline in total EQ-5D
score
1 Mean Difference (Fixed, 95% CI) Totals not selected
6.1 at 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 at 12 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Health-related QoL: change
from baseline in EQ-5D VAS
score
2 Mean Difference (Fixed, 95% CI) Subtotals only
7.1 at 6 months 2 58 Mean Difference (Fixed, 95% CI) 4.11 [-3.66, 11.88]
7.2 at 12 months 1 25 Mean Difference (Fixed, 95% CI) 9.9 [-5.93, 25.73]
8 Health-related QoL: change
from baseline in EQ-5D Utility
score
1 Mean Difference (Fixed, 95% CI) Totals not selected
8.1 at 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Health-related QoL: change
from baseline in SF 36 Physical
Functioning Score
1 Mean Difference (Fixed, 95% CI) Totals not selected
9.1 at 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Health-related QoL: change
from baseline in SF 36 Physical
Score
1 Mean Difference (Fixed, 95% CI) Totals not selected
10.1 at 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Health-related QoL: change
from baseline in SF 36 Bodily
Pain Score
1 Mean Difference (Fixed, 95% CI) Totals not selected
11.1 at 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
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12 Health-related QoL: change
from baseline in SF 36 General
Health Score
1 Mean Difference (Fixed, 95% CI) Totals not selected
12.1 at 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Health-related QoL: change
from baseline in SF 36 Vitality
/ Energy Score
1 Mean Difference (Fixed, 95% CI) Totals not selected
13.1 at 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Health-related QoL: change
from baseline in SF 36 Social
Functioning Score
1 Mean Difference (Fixed, 95% CI) Totals not selected
14.1 at 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Health-related QoL: change
from baseline in SF 36
Emotional Score
1 Mean Difference (Fixed, 95% CI) Totals not selected
15.1 at 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Health-related QoL: change
from baseline in SF 36 Mental
Health Score
1 Mean Difference (Fixed, 95% CI) Totals not selected
16.1 at 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Health-related QoL: change
from baseline in SF 36 Physcial
Summary Score
1 Mean Difference (Fixed, 95% CI) Totals not selected
17.1 at 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Health-related QoL: change
from baseline in SF 36 Mental
Summary Score
1 Mean Difference (Fixed, 95% CI) Totals not selected
18.1 at 6 months 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. High-dose compared to low-dose recombinant factor VIIIa (rFVIIIa)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall bleeding rates: number
of bleeds per month
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Target joint bleeding rate:
number of joint bleeds over 3
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Number of adverse events 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 200 µg/kg vs 100 µg/kg 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 200 µg/kg vs 25 µg/kg 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 100 µg/kg vs 25 µg/kg 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 270 µg/kg vs 90 µg/kg 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Number of serious adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 1 Overall bleeding rates: total number of
bleeding events.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 1 Overall bleeding rates: total number of bleeding events
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 6 months
Leissinger 2011 26 26 -7.269231 (1.353693) -7.27 [ -9.92, -4.62 ]
-10 -5 0 5 10
Favours prophylaxis Favours on-demand
Analysis 1.2. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 2 Overall bleeding rates: number of monthly
bleeding events.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 2 Overall bleeding rates: number of monthly bleeding events
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 up to 6 months
Leissinger 2011 26 26 -1.1 (0.224458) -1.10 [ -1.54, -0.66 ]
-2 -1 0 1 2
Favours prophylaxis Favours on-demand
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Analysis 1.3. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 3 Target joint bleeding rate: number of
hemarthroses.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 3 Target joint bleeding rate: number of hemarthroses
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 6 months
Leissinger 2011 26 26 -6.6 (1.387237) -6.60 [ -9.32, -3.88 ]
-10 -5 0 5 10
Favours prophylaxis Favours on-demand
Analysis 1.4. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 4 Target joint bleeding rate: number of joint
hemorrhages.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 4 Target joint bleeding rate: number of joint hemorrhages
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 6 months
Leissinger 2011 26 26 -0.9 (0.236157) -0.90 [ -1.36, -0.44 ]
-2 -1 0 1 2
Favours prophylaxis Favours on-demand
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Analysis 1.5. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 5 Health-related QoL: change from baseline
in total Haem-A-QoL score.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 5 Health-related QoL: change from baseline in total Haem-A-QoL score
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 12 months
Antunes 2014 9 14 3.4 (4.5582) 3.40 [ -5.53, 12.33 ]
-20 -10 0 10 20
Favours on-demand Favours prophylaxis
Analysis 1.6. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 6 Health-related QoL: change from baseline
in total EQ-5D score.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 6 Health-related QoL: change from baseline in total EQ-5D score
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 6 months
Antunes 2014 11 15 0.09 (0.0904) 0.09 [ -0.09, 0.27 ]
2 at 12 months
Antunes 2014 10 15 0.07 (0.1045) 0.07 [ -0.13, 0.27 ]
-0.5 -0.25 0 0.25 0.5
Favours on-demand Favours prophylaxis
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Analysis 1.7. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 7 Health-related QoL: change from baseline
in EQ-5D VAS score.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 7 Health-related QoL: change from baseline in EQ-5D VAS score
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 6 months
Antunes 2014 11 15 15.3 (6.8203) 33.8 % 15.30 [ 1.93, 28.67 ]
Leissinger 2011 16 16 -1.6 (4.873199) 66.2 % -1.60 [ -11.15, 7.95 ]
Subtotal (95% CI) 27 31 100.0 % 4.11 [ -3.66, 11.88 ]
Heterogeneity: Chi2 = 4.06, df = 1 (P = 0.04); I2 =75%
Test for overall effect: Z = 1.04 (P = 0.30)
2 at 12 months
Antunes 2014 10 15 9.9 (8.0756) 100.0 % 9.90 [ -5.93, 25.73 ]
Subtotal (95% CI) 10 15 100.0 % 9.90 [ -5.93, 25.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
-100 -50 0 50 100
Favours on-demand Favours prophylaxis
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Analysis 1.8. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 8 Health-related QoL: change from baseline
in EQ-5D Utility score.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 8 Health-related QoL: change from baseline in EQ-5D Utility score
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 6 months
Leissinger 2011 16 16 0 (0.059672) 0.0 [ -0.12, 0.12 ]
-0.5 -0.25 0 0.25 0.5
Favours on-demand Favours prophylaxis
Analysis 1.9. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 9 Health-related QoL: change from baseline
in SF 36 Physical Functioning Score.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 9 Health-related QoL: change from baseline in SF 36 Physical Functioning Score
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 6 months
Leissinger 2011 18 18 -2.5 (4.904891) -2.50 [ -12.11, 7.11 ]
-100 -50 0 50 100
Favours on-demand Favours prophylaxis
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Analysis 1.10. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 10 Health-related QoL: change from baseline
in SF 36 Physical Score.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 10 Health-related QoL: change from baseline in SF 36 Physical Score
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 6 months
Leissinger 2011 18 18 12.7 (12.74298) 12.70 [ -12.28, 37.68 ]
-100 -50 0 50 100
Favours on-demand Favours prophylaxis
Analysis 1.11. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 11 Health-related QoL: change from baseline
in SF 36 Bodily Pain Score.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 11 Health-related QoL: change from baseline in SF 36 Bodily Pain Score
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 6 months
Leissinger 2011 18 18 14.3 (7.404617) 14.30 [ -0.21, 28.81 ]
-100 -50 0 50 100
Favours on-demand Favours prophylaxis
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Analysis 1.12. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 12 Health-related QoL: change from baseline
in SF 36 General Health Score.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 12 Health-related QoL: change from baseline in SF 36 General Health Score
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 6 months
Leissinger 2011 18 18 4.3 (4.593763) 4.30 [ -4.70, 13.30 ]
-100 -50 0 50 100
Favours on-demand Favours prophylaxis
Analysis 1.13. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 13 Health-related QoL: change from baseline
in SF 36 Vitality / Energy Score.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 13 Health-related QoL: change from baseline in SF 36 Vitality / Energy Score
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 6 months
Leissinger 2011 18 18 -5.8 (3.940259) -5.80 [ -13.52, 1.92 ]
-100 -50 0 50 100
Favours on-demand Favours prophylaxis
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Analysis 1.14. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 14 Health-related QoL: change from baseline
in SF 36 Social Functioning Score.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 14 Health-related QoL: change from baseline in SF 36 Social Functioning Score
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 6 months
Leissinger 2011 18 18 4.8 (6.549986) 4.80 [ -8.04, 17.64 ]
-100 -50 0 50 100
Favours on-demand Favours prophylaxis
Analysis 1.15. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 15 Health-related QoL: change from baseline
in SF 36 Emotional Score.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 15 Health-related QoL: change from baseline in SF 36 Emotional Score
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 6 months
Leissinger 2011 18 18 11.1 (10.00133) 11.10 [ -8.50, 30.70 ]
-100 -50 0 50 100
Favours on-demand Favours prophylaxis
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Analysis 1.16. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 16 Health-related QoL: change from baseline
in SF 36 Mental Health Score.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 16 Health-related QoL: change from baseline in SF 36 Mental Health Score
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 6 months
Leissinger 2011 18 18 -3.1 (4.395512) -3.10 [ -11.72, 5.52 ]
-100 -50 0 50 100
Favours on-demand Favours prophylaxis
Analysis 1.17. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 17 Health-related QoL: change from baseline
in SF 36 Physcial Summary Score.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 17 Health-related QoL: change from baseline in SF 36 Physcial Summary Score
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 6 months
Leissinger 2011 18 18 2.9 (2.261418) 2.90 [ -1.53, 7.33 ]
-100 -50 0 50 100
Favours on-demand Favours prophylaxis
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Analysis 1.18. Comparison 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC)
or factor eight inhibitor bypassing activity (FEIBA NF), Outcome 18 Health-related QoL: change from baseline
in SF 36 Mental Summary Score.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 1 Prophylaxis compared to on-demand anti-inhibitor coagulant complex (AICC) or factor eight inhibitor bypassing activity (FEIBA NF)
Outcome: 18 Health-related QoL: change from baseline in SF 36 Mental Summary Score
Study or subgroup Prophylaxis On-demand Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 6 months
Leissinger 2011 18 18 1.2 (2.013677) 1.20 [ -2.75, 5.15 ]
-100 -50 0 50 100
Favours on-demand Favours prophylaxis
Analysis 2.1. Comparison 2 High-dose compared to low-dose recombinant factor VIIIa (rFVIIIa), Outcome
1 Overall bleeding rates: number of bleeds per month.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 2 High-dose compared to low-dose recombinant factor VIIIa (rFVIIIa)
Outcome: 1 Overall bleeding rates: number of bleeds per month
Study or subgroup 270 g/kg 90 g/kg
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Konkle 2007 11 2.182 (1.682) 11 3 (1.79) -0.82 [ -2.27, 0.63 ]
-10 -5 0 5 10
Favours 270 g/kg Favours 90 g/kg
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Analysis 2.2. Comparison 2 High-dose compared to low-dose recombinant factor VIIIa (rFVIIIa), Outcome
2 Target joint bleeding rate: number of joint bleeds over 3 months.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 2 High-dose compared to low-dose recombinant factor VIIIa (rFVIIIa)
Outcome: 2 Target joint bleeding rate: number of joint bleeds over 3 months
Study or subgroup 270 g/kg 90 g/kg
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Konkle 2007 11 4.7 (4.3) 11 7.9 (5.3) -3.20 [ -7.23, 0.83 ]
-20 -10 0 10 20
Favours 270 g/kg Favours 90 g/kg
Analysis 2.3. Comparison 2 High-dose compared to low-dose recombinant factor VIIIa (rFVIIIa), Outcome
3 Number of adverse events.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 2 High-dose compared to low-dose recombinant factor VIIIa (rFVIIIa)
Outcome: 3 Number of adverse events
Study or subgroup High dose Low dose Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 200 g/kg vs 100 g/kg
Ljung 2013 6/8 6/8 1.00 [ 0.57, 1.76 ]
2 200 g/kg vs 25 g/kg
Ljung 2013 6/8 4/8 1.50 [ 0.67, 3.34 ]
3 100 g/kg vs 25 g/kg
Ljung 2013 6/8 4/8 1.50 [ 0.67, 3.34 ]
4 270 g/kg vs 90 g/kg
Konkle 2007 8/11 9/11 0.89 [ 0.56, 1.40 ]
0.01 0.1 1 10 100
Favours High dose Favours Low dose
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Analysis 2.4. Comparison 2 High-dose compared to low-dose recombinant factor VIIIa (rFVIIIa), Outcome
4 Number of serious adverse events.
Review: Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Comparison: 2 High-dose compared to low-dose recombinant factor VIIIa (rFVIIIa)
Outcome: 4 Number of serious adverse events
Study or subgroup 270 g/kg 90 g/kg Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Konkle 2007 4/11 0/11 9.00 [ 0.54, 149.50 ]
0.01 0.1 1 10 100
Favours 270 g/kg Favours 90 g/kg
A P P E N D I C E S
Appendix 1. Online trials databases - search strategies
Clinicaltrials.gov
Advanced Search Form
Search terms: haemophilia AND inhibitor AND prophylaxis
Study type: Interventional Studies
WHO ICTRP
Advanced Search Form
Condition: inhibitor* AND haemophilia* OR hemophilia*
Intervention: prophyla*
[Recruitment status: ALL]
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